Related Experiment Video

Updated: Jun 16, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

The potential role of sunitinib in gastrointestinal cancers other than GIST

Cristina Grávalos1, Enrique Grande, Joan Manel Gasent

  • 1Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain. cgravalos@telefonica.net

Critical Reviews in Oncology/Hematology
|February 6, 2010
PubMed

Insights

Sunitinib, a targeted therapy inhibiting VEGF and other pathways, shows dual anti-tumor and anti-angiogenic effects. This review examines its preclinical basis and clinical data in gastrointestinal cancers beyond GIST.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal tumors represent a significant global health burden.
  • Targeted therapies, including EGFR and VEGF inhibitors, are advancing cancer treatment.
  • Sunitinib is an oral multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumoral properties.

Purpose of the Study:

  • To review the preclinical rationale for sunitinib's use in gastrointestinal malignancies.
  • To summarize available clinical trial data (Phase I-III) for sunitinib in these cancers, excluding GIST.

Main Methods:

  • Literature review of preclinical studies.
  • Systematic compilation and analysis of clinical trial data.

Main Results:

  • Preclinical data support sunitinib's efficacy through inhibition of key signaling pathways.
  • Clinical data from various phases are being evaluated for specific gastrointestinal tumor types.

Conclusions:

  • Sunitinib demonstrates a strong preclinical foundation for treating gastrointestinal cancers.
  • Further clinical evaluation is crucial to establish sunitinib's role in non-GIST gastrointestinal malignancies.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...